Skip to main content
Adoptive T-cell immunotherapy to treat cancer caused by Epstein-Barr virus

Adoptive T-cell immunotherapy to treat cancer caused by Epstein-Barr virus

Unmet Need Epstein-Barr virus (EBV) is an infectious disease that has been shown to cause a number of cancers originating from EBV-afflicted cells. Across the globe, EBV is associated with approximately 200,000 cases of malignancies…

Read More

Anti-LYPD3 CAR T-cell therapy for the treatment of squamous cell carcinoma

Anti-LYPD3 CAR T-cell therapy for the treatment of squamous cell carcinoma

Unmet Need Chimeric Antigen Receptor (CAR) T-cell therapy, a form of immunotherapy, has proven highly effective against blood cancers such as leukemias and lymphomas. This therapy uses T-cells that are genetically engineering ex vivo to…

Read More

A novel T-cell-based immunotherapy for brain cancer

A novel T-cell-based immunotherapy for brain cancer

Unmet Need Cancer immunotherapy represents a new paradigm in cancer treatment with the goal of harnessing the immune system to selectively attack a patient’s tumor. T-cell-based immunotherapies encompass chimeric antigen receptor (CAR)-T cells, tumor-infiltrating lymphocytes,…

Read More

Anti-cancer therapeutic for the induction of apoptosis in solid tumors via TRAIL receptors

Anti-cancer therapeutic for the induction of apoptosis in solid tumors via TRAIL receptors

Unmet Need Tumor necrosis factor-Related Apoptosis-Inducing Ligand (TRAIL, CD253) acts as an activator of apoptosis in many tumor cells, while remaining innocuous to normal cells. Both membrane-bound and soluble forms of TRAIL can trigger apoptosis…

Read More

Enzymatic synthesis of aptamer-targeted polynucleotide drug delivery platforms for cancer therapy

Enzymatic synthesis of aptamer-targeted polynucleotide drug delivery platforms for cancer therapy

Unmet Need In the United States alone, over 1.8 million new patients were diagnosed with cancer in 2021, and over 600,000 patients died from the disease. Cytostatic nucleotides, such as gemcitabine and 5-fluorouracil, have been…

Read More

A class of biodegradable stealth polymers to improve drug delivery

A class of biodegradable stealth polymers to improve drug delivery

Unmet Need Delivery of drugs or therapeutics such as small molecules, peptides, and proteins, in their native form, is limited by their poor stability, low solubility, and short in vivo circulation. These challenges in drug…

Read More

A method for treating TRAIL-resistant cancers

A method for treating TRAIL-resistant cancers

Unmet Need Over the past twenty years, TNF-related apoptosis-inducing ligand (TRAIL) has been shown to kill a variety of human cancer cells in vitro and in vivo while remaining innocuous to healthy cells. Unfortunately, the…

Read More

Have Questions?

Please contact us or subscribe for more opportunities

Stay in Touch with Us